~~<i id='2E95CD2FE6'><strike id='2E95CD2FE6'><tt id='2E95CD2FE6'><pre id='2E95CD2FE6'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：comprehensive 2025-10-04 07:02:02 Page View：1

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work
Next article： Medicare details structure of new drug price negotiation program

leisure time

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Roivant's CEO is a star, but biotech's black hole persists

MollyFerguson/STATRoivantSciences’MattGlinemightbethisyear’sbestbiopharmaCEO,andotherthoughtsaboutMo

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

FILE-HandgunsaredisplayedatagunshoponJune,23,2022,inHonolulu.ThreeHawaiiresidentschallengingthestate

WSS

comprehensive

comprehensive

knowledge

leisure time

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches